Research Articles | Page 28 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Considerations for Drug Development in Myelodysplastic Syndromes Jul 2023 Clinical Cancer Research Myelodysplastic Syndromes (MDS)
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes Jul 2023 European Journal of Haematology Myelodysplastic Syndromes (MDS)
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress Jul 2023 Expert Review of Anticancer Therapies Myelodysplastic Syndromes (MDS)
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria Jul 2023 Clinical and Experimental Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes Jul 2023 Blood Advances Myelodysplastic Syndromes (MDS)
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study Jul 2023 Blood Advances Myelodysplastic Syndromes (MDS)
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care Jul 2023 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? Jul 2023 Lancet Myelodysplastic Syndromes (MDS)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Jul 2023 Lancet Myelodysplastic Syndromes (MDS)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)